Hickory Point Bank & Trust Cuts Holdings in Pfizer Inc. $PFE

Hickory Point Bank & Trust reduced its position in Pfizer Inc. (NYSE:PFE) by 6.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 15,487 shares of the biopharmaceutical company’s stock after selling 997 shares during the quarter. Hickory Point Bank & Trust’s holdings in Pfizer were worth $375,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in PFE. Bessemer Group Inc. raised its position in Pfizer by 11.1% in the first quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company’s stock valued at $3,358,000 after purchasing an additional 13,228 shares during the period. Capital Advisors Inc. OK raised its position in Pfizer by 1.2% in the first quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company’s stock valued at $35,817,000 after purchasing an additional 17,032 shares during the period. CHURCHILL MANAGEMENT Corp purchased a new position in Pfizer in the first quarter valued at about $8,283,000. Westbourne Investments Inc. purchased a new position in Pfizer in the first quarter valued at about $2,411,000. Finally, Alta Advisers Ltd raised its position in Pfizer by 69.6% in the first quarter. Alta Advisers Ltd now owns 31,912 shares of the biopharmaceutical company’s stock valued at $809,000 after purchasing an additional 13,100 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Stock Down 3.8%

NYSE:PFE opened at $23.91 on Monday. The company has a market capitalization of $135.94 billion, a price-to-earnings ratio of 12.72, a price-to-earnings-growth ratio of 0.85 and a beta of 0.55. Pfizer Inc. has a one year low of $20.92 and a one year high of $30.43. The stock has a 50-day simple moving average of $24.79 and a 200 day simple moving average of $24.27. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. The business had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period last year, the firm earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Sell-side analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were issued a $0.43 dividend. The ex-dividend date of this dividend was Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a yield of 7.2%. Pfizer’s dividend payout ratio (DPR) is currently 91.49%.

Wall Street Analyst Weigh In

Several research analysts have commented on PFE shares. Jefferies Financial Group raised their price objective on Pfizer from $32.00 to $33.00 and gave the company a “buy” rating in a research report on Wednesday, May 21st. Bank of America raised their target price on Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Berenberg Bank lowered their target price on Pfizer from $28.00 to $25.00 and set a “hold” rating for the company in a research note on Thursday, May 29th. Citigroup raised their target price on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Finally, HSBC lowered their target price on Pfizer from $27.00 to $26.00 and set a “buy” rating for the company in a research note on Monday, May 19th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $28.12.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.